Book a meeting
DO-BO

Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)

This is a repost of a popular MAP, Market Access Podcast, from January 2023. 

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 

Related

Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günther Illert?

By

Stefan Walzer

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education. Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock […]

Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?

By

Stefan Walzer

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]

Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?

By

Stefan Walzer

In this brand new episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes. From streamlining evidence generation to enhancing pricing strategies and dossier creation, […]